ORXOY (Orexo AB) Net Income From Continuing Operations: $-32.26 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORXOY Orexo AB ORXOY
35 GF Score
Price $1.39
GF Value $0.39
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Orexo AB Net Income From Continuing Operations?

Orexo AB ORXOY 35 Net Income From Continuing Operations is $-32.26 Mil as of Jun. 2026. GuruFocus rates ORXOY with a GF Score™ of 35/100 and a GF Value™ of $0.39 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Orexo AB's net income from continuing operations for the three months ended in Jun. 2026 was $-10.86 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-32.26 Mil.

Orexo AB Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Orexo AB's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB Net Income From Continuing Operations Chart

Orexo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.55 -17.72 -10.68 -38.89 -37.95

Orexo AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.93 -2.25 -11.11 -8.05 -10.86
ORXOY
35GF Score
Orexo AB ORXOY
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orexo AB Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of $-32.26 Mil mean?
Orexo AB (ORXOY) has a Net Income From Continuing Operations of $-32.26 Mil as of Jun. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Orexo AB and its competitors.
Is Orexo AB's Net Income From Continuing Operations too high?
Orexo AB's current Net Income From Continuing Operations is $-32.26 Mil. Overall, Orexo AB has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Net Income From Continuing Operations compare to ZTS?
Orexo AB's Net Income From Continuing Operations of $-32.26 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Drug Manufacturers company?
A good Net Income From Continuing Operations depends on the Drug Manufacturers industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Orexo AB and its competitors. Orexo AB's current Net Income From Continuing Operations is $-32.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOY) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.39, compared to a current price of $1.39 — trading 256.4% above its estimated fair value. The current Net Income From Continuing Operations is $-32.26 Mil. Orexo AB's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Orexo AB (ORXOY), the current Net Income From Continuing Operations is $-32.26 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orexo AB (ORXOY) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of $1.39 is trading 256.4% above its estimated GF Value™ of $0.39. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for ORXOY:

  • Net Income From Continuing Operations: $-32.26 Mil
  • GF Value™: $0.39 vs. price of $1.39 (256.4% above fair value)
  • GF Score™: 35/100 with 7 warning signs

No single metric tells the full story. See the ORXOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
35GF Score

Get the complete analysis for ORXOY

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.39
Price
$0.39
GF Value